HomeBUSINESS
BUSINESS

JT and Bayer Begin Japan PIII for HIF-PH Inhibitors, Follow Astellas and GSK
(Oct.4.2017)

Japan Tobacco and Bayer Yakuhin have recently launched PIII trials in Japan for their hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors - a class of medicines seen as post-erythropoiesis stimulating agents (ESAs) for renal anemia treatment where Astellas Pharma and GlaxoSmithKline have a slight lead in the country ...
(LOG IN FOR FULL STORY)

News Calendar